Update on the use of rituximab for intractable rheumatoid arthritis
R John LooneyUniversity of Rochester, Rochester, New York, USAAbstract: It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA) with an ina...
Saved in:
| Main Author: | |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2009
|
| Subjects: | |
| Online Access: | https://doaj.org/article/967a4a12fae44754a99f5bcadd572bbe |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|